Xervyteg® (MaaT013): Positive Topline Phase 3 Results

EMA Submission Completed – See more

Enhancing Survival Through Innovative Immune Modulation

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

June 27, 2025

June 25, 2025: Just the Two of Us: Creating Microbiomes to Fight Cancer, ALS, and More – Inside Precision Medicine

June 24, 2025

June 24, 2025: MaaT Pharma Presents the Results of its Annual Ordinary and Extraordinary General Meeting

June 19, 2025

June 19, 2025: MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025

Like what you see? See more posts

Our upcoming events

Event
June 30, 2025

EHA 2025 Congress

• June 12-15, 2025 – EHA 2025 Congress, Milan, Italy
MaaT Pharma
Event
June 30, 2025

BIO International Convention 2025

• June 16-19, 2025 – BIO International Convention 2025, Boston, MA
MaaT Pharma
Event
June 30, 2025

KBC Healthcare Conference 2025

• September 25, 2025 – KBC Healthcare Conference, Brussels
MaaT Pharma

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!

Careers